drugset
drugset / Trial / NCT05408780

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

NCT05408780 ↗

Phase 1 Completed 45 enrolled Cerecin
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid formulation of tricaprilin.

Timeline

Start
2022-07-14
Primary completion
2022-08-13
Completion
2022-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Tricaprilin Other / unclassified — —

Indications

Alzheimer disease